Fetal antiepileptic drug exposure and cognitive outcomes

详细信息    查看全文

• 作者：Rebecca L. Bromley^a ; ^b ; ^{Rebecca.bromley@manchester.ac.uk} ; ^{rebecca.bromley@cmft.nhs.uk} ; Gus A. Baker^c
• 关键词：Epilepsy ; Pregnancy ; In utero ; Antiepileptic drugs ; Neurodevelopment
• 刊名：Seizure
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：44
• 期：Complete
• 页码：225-231
• 全文大小：374 K
• 卷排序：44

文摘

Data highlighting valproate as a human teratogen put in context the need to balance both maternal and fetal needs; maximising maternal health whilst minimising fetal risk. This led to increased research efforts to understand the associated risks with AED treatments.MethodsA review of currently published literature was undertaken.ResultsIn utero exposure to valproate was associated with a range of poorer neurodevelopmental outcomes when compared to control children and children exposed to other antiepileptic drugs (AEDs). Children exposed to carbamazepine were not found by the majority of studies to have poorer early development, although there is a lack of evidence regarding specific cognitive skills later in childhood and adolescence. Research regarding lamotrigine was limited to a small number of studies but suggests early global development or school aged IQ does not differ from control children, but less is known about specific cognitive skills. Evidence for the other AEDs including levetiracetam and topiramate were significantly limited.ConclusionsDespite an improvement in momentum the evidence remains incomplete for neurodevelopmental outcomes and this limits evidence-based decision making. Further efforts are required to enhance the treatment of women by giving them the confidence that both the risks and the benefits of commonly used AEDs are known. Future research should also seek to increase our understanding of the children who experience neurodevelopmental difficulties in the context of exposure in the womb to AEDs and what interventions may be successful in maximising the outcome of these children.